Did Gabrielle Union publicly confirm using hormones?

Yes. Union has confirmed undergoing multiple IVF cycles involving injectable fertility hormones and has publicly discussed her perimenopause symptoms. She has not confirmed whether she currently uses menopausal hormone therapy.

Is IVF hormone therapy the same as menopausal HRT?

No. IVF uses high-dose gonadotropins and GnRH modulators for short periods to stimulate egg production. Menopausal HRT uses lower-dose estrogen and progesterone over longer periods to manage symptoms like hot flashes and bone loss. The drugs, doses, durations, and goals are different.

Does adenomyosis affect HRT decisions during perimenopause?

It can. Adenomyosis is estrogen-dependent, so introducing exogenous estrogen through HRT may theoretically reactivate symptoms. Clinicians typically weigh the severity of vasomotor symptoms against this risk. Many women with a history of adenomyosis can still use HRT safely with appropriate monitoring.

When does perimenopause typically begin?

Most women enter perimenopause in their mid-40s, though it can begin as early as the late 30s. The transition typically lasts 4 to 8 years before final menstruation. Symptoms include irregular cycles, hot flashes, sleep disruption, and mood changes.

Can prior IVF treatments affect later menopause timing?

Current evidence is mixed. Some studies suggest that high-dose ovarian stimulation does not significantly alter the timing of menopause, while others indicate a modest association. A 2020 study in *Human Reproduction* found no clinically significant difference in age at menopause among women who had undergone IVF compared to those who had not.

Gabrielle Union and Women's HRT: The Documented Public Record

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

The Public Record: What Gabrielle Union Has Confirmed

Gabrielle Union's public timeline with hormone-related medical interventions spans more than a decade. She has been unusually transparent about the physical and emotional toll of these treatments, making her story a touchstone in conversations about women's reproductive health.

Fertility Treatments and IVF

Union has confirmed undergoing multiple rounds of IVF and fertility treatments, disclosing that she experienced "eight or nine" failed IVF cycles before her daughter Kaavia James was born via surrogate in November 2018. In her 2017 memoir We're Going to Need More Wine, she wrote candidly about the hormonal protocols involved, describing the injections, mood swings, and physical discomfort that accompanied each cycle.

IVF protocols typically involve controlled ovarian hyperstimulation using injectable gonadotropins (follicle-stimulating hormone, or FSH, and luteinizing hormone, or LH), often combined with gonadotropin-releasing hormone (GnRH) agonists or antagonists to prevent premature ovulation. Progesterone supplementation is standard during the luteal phase and early pregnancy support. A 2019 review in The Lancet confirmed that these protocols carry measurable side effects including ovarian hyperstimulation syndrome (OHSS), bloating, breast tenderness, and significant mood variability.

Union described these side effects publicly, telling People magazine that the hormonal fluctuations left her feeling "broken" physically. The HealthRX Medical Team notes that this description aligns with well-documented patient-reported outcomes during IVF: the supraphysiologic estradiol levels achieved during stimulation (often 1,000 to 3,000 pg/mL, compared to a normal mid-cycle peak of roughly 200 to 400 pg/mL) can produce pronounced emotional and somatic symptoms.

Adenomyosis Diagnosis

Union has also publicly confirmed a diagnosis of adenomyosis, a condition in which endometrial tissue grows into the muscular wall of the uterus. She has described the condition as a significant contributor to both her fertility challenges and her painful periods.

Adenomyosis affects an estimated 20% to 35% of women, though prevalence estimates vary by diagnostic method. According to a 2020 study published in JAMA, adenomyosis is associated with reduced IVF success rates, with some data suggesting a 28% lower odds of live birth per transfer cycle. Hormonal management of adenomyosis-related symptoms often involves GnRH agonist pretreatment before IVF cycles, oral progestins, or the levonorgestrel intrauterine system.

Perimenopause Disclosure

More recently, Union has spoken about her perimenopause experience. In a 2022 interview, she described symptoms including sleep disruption, hot flashes, and brain fog, noting that she initially did not recognize these as perimenopausal because she associated menopause with older women.

This disclosure matters clinically because perimenopause can begin in a woman's early to mid-40s (Union was born in 1972). The North American Menopause Society defines perimenopause as the transitional period marked by irregular menstrual cycles and fluctuating estrogen levels before final menstruation. Symptoms can persist for 4 to 8 years.

Clinical Context: Hormone Therapy in Fertility and Perimenopause

Fertility Hormones vs. Menopausal HRT

A common point of confusion, and one the HealthRX Medical Team emphasizes, is that the hormones used in IVF protocols differ substantially from those used in menopausal hormone therapy (MHT), even though both fall under the broad umbrella of "hormone therapy."

IVF hormones are administered at supraphysiologic doses for short durations (typically 10 to 14 days per cycle) with the goal of producing multiple mature oocytes. The primary agents are injectable gonadotropins (FSH and LH), GnRH agonists or antagonists, hCG trigger shots, and luteal-phase progesterone. Side effects include OHSS, mood changes, injection-site reactions, headaches, and abdominal distension.

Menopausal HRT uses lower, physiologic-replacement doses of estrogen (with or without progesterone) over months to years to manage vasomotor symptoms, sleep disturbance, urogenital atrophy, and bone density loss. The 2022 Menopause Society position statement supports initiation of systemic MHT in symptomatic women under age 60 or within 10 years of menopause onset, noting that benefits generally outweigh risks in this window.

What the Evidence Shows for Perimenopausal Women

For women experiencing the symptoms Union has described (hot flashes, sleep disruption, cognitive fog), current evidence supports several approaches:

Systemic estrogen therapy remains the most effective treatment for vasomotor symptoms. A Cochrane review found that oral or transdermal estrogen reduced hot flash frequency by approximately 75% compared to placebo.

Low-dose oral contraceptives can be used in perimenopausal women who still require contraception, offering cycle regulation alongside symptom relief. ACOG guidelines support this approach in healthy, non-smoking women up to age 50.

Progesterone (particularly micronized progesterone at 100 to 200 mg nightly) has demonstrated sleep-promoting properties independent of its endometrial protective role, according to the Endocrine Society's 2015 clinical practice guidelines.

The HealthRX Medical Team notes that Union's prior exposure to high-dose fertility hormones does not preclude safe use of menopausal HRT. The clinical considerations are distinct: IVF-related hormone exposure is acute, while MHT is chronic but at much lower doses.

At a glance

Confirmed: Gabrielle Union has publicly confirmed multiple IVF cycles, a diagnosis of adenomyosis, and perimenopause symptoms including hot flashes, sleep disruption, and cognitive fog.
Not publicly confirmed: Whether Union is currently using any form of menopausal hormone therapy (systemic estrogen, transdermal patches, or progesterone) for her perimenopausal symptoms. She has described symptoms but has not publicly disclosed a specific HRT regimen.
Clinical relevance: IVF hormones and menopausal HRT serve different purposes at different doses. A history of IVF does not create contraindications for later menopausal HRT in most women.
Adenomyosis factor: This confirmed diagnosis adds clinical complexity to both fertility treatment planning and symptom management during perimenopause, as the condition is estrogen-dependent.

The HealthRX Medical Team Take

Union's public record is notable for its specificity. Unlike many celebrity disclosures that mention "hormone issues" without detail, she has named the condition (adenomyosis), described the treatments (IVF with injectable hormones), quantified the attempts (eight or nine cycles), and discussed the emotional consequences without minimizing them.

This specificity has clinical value for public health communication. Research published in the Journal of Health Communication has shown that celebrity health disclosures can increase public awareness and health-seeking behavior, particularly when the disclosure includes actionable medical detail rather than vague references.

The HealthRX Medical Team observes that Union's story also highlights a gap many women experience: the transition from fertility treatment to perimenopause management. Women who undergo IVF in their late 30s or early 40s may enter perimenopause within a few years of completing fertility treatment, yet these two phases of hormonal medicine are typically managed by different specialists (reproductive endocrinologists vs. gynecologists or menopause specialists). Union's public account illustrates why continuity of hormonal care matters.

One clinical nuance worth emphasizing: adenomyosis is an estrogen-dependent condition, which means that decisions about menopausal HRT require careful consideration of symptom burden versus potential for disease reactivation. The European Society of Human Reproduction and Embryology notes that while adenomyosis symptoms typically improve after menopause due to declining estrogen, exogenous estrogen replacement could theoretically reactivate symptoms in some women. This is a conversation Union's medical team would need to manage on an individualized basis.

What Has Not Been Publicly Confirmed

Union has not publicly disclosed:

Whether she is currently taking any form of menopausal hormone therapy
Specific drug names, doses, or formulations for any current hormonal treatment
Whether she has used bioidentical versus conventional hormone preparations
Whether her adenomyosis has been managed surgically or medically in the perimenopausal period

The HealthRX Medical Team does not speculate on these points. Public figures are entitled to selective disclosure, and clinical recommendations should not be inferred from the absence of public statements.

Frequently asked questions

›

References

North American Menopause Society. "The 2022 Hormone Therapy Position Statement." menopause.org
The Lancet. "IVF and Ovarian Stimulation Protocols." 2019. thelancet.com
JAMA. "Adenomyosis and IVF Outcomes." 2020. jamanetwork.com
Endocrine Society. "Clinical Practice Guidelines: Treatment of Symptoms of the Menopause." 2015. endocrine.org
Cochrane Database. "Hormone Therapy for Hot Flashes." pubmed.ncbi.nlm.nih.gov
People Magazine. Gabrielle Union fertility interviews. people.com
SELF Magazine. Gabrielle Union perimenopause interview. 2022. self.com